QUVIVIQ sales increased 62% year-on-year as Idorsia advances key drivers of future growth
· idorsia pharmaceuticals ltd
Source Summary
Ad hoc announcement pursuant to Art. 53 LR QUVIVIQTM (daridorexant) sales reached CHF 91 million in H1 2026, up 62% year-on-year. Full-year 2026 guidance...
Advertisement